Related Experiment Videos
Multidrug resistance in haematological malignancies
X R Jiang1, M G Macey, A C Newland
1Dept of Haematology, Royal London Hospital, Whitechapel, England, UK.
Medical Laboratory Sciences
|October 1, 1991
Summary
Patients with blood disorders often develop multidrug resistance (MDR), a challenge in cancer treatment. This review examines the underlying mechanisms and factors contributing to MDR development over the past decade.
Area of Science:
- Hematology
- Pharmacology
- Molecular Biology
Background:
- Many patients with hematological disorders exhibit resistance to chemotherapy.
- This resistance, known as multidrug resistance (MDR), affects a broad spectrum of chemotherapeutic agents.
- Understanding MDR is crucial for improving treatment efficacy in blood cancers.
Purpose of the Study:
- To review and synthesize current knowledge on the mechanisms of multidrug resistance (MDR) in hematological disorders.
- To examine the factors contributing to the development of MDR.
- To provide an updated overview of MDR research over the last ten years.
Main Methods:
- Literature review of scientific publications.
- Analysis of research on multidrug resistance (MDR) mechanisms.
- Synthesis of current concepts in the field.
Main Results:
- Significant advancements have been made in understanding the molecular basis of MDR.
- Various cellular and genetic factors contribute to the development of multidrug resistance (MDR).
- The review consolidates recent findings on MDR mechanisms.
Conclusions:
- The mechanisms underlying multidrug resistance (MDR) are becoming increasingly understood.
- Further research into MDR factors may lead to novel therapeutic strategies.
- Addressing MDR is essential for overcoming treatment challenges in hematological malignancies.